Global Neurodegenerative Disease Treatment Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Market Analysis by Type
  • 1.3.1 Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type: 2020 VS 2026
  • 1.3.2 Neurotransmitter Agents
  • 1.3.3 Neuroprotective Agents
  • 1.3.4 Biologics
  • 1.3.5 Others
• 1.4 Market by Application
  • 1.4.1 Global Neurodegenerative Disease Treatment Market Share by Application: 2020 VS 2026
  • 1.4.2 Multiple Sclerosis [MS]
  • 1.4.3 Alzheimer’s Disease
  • 1.4.4 Parkinson's Disease
  • 1.4.5 Acute Migraine
  • 1.4.6 Autism
  • 1.4.7 Narcolepsy
  • 1.4.8 Amyotrophic Lateral Sclerosis [ALS]
  • 1.4.9 Attention Deficit Hyperactivity Disorder [ADHD]
  • 1.4.10 Spinal Muscular Atrophy
  • 1.4.11 Huntington's Disease
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Neurodegenerative Disease Treatment Market Perspective (2015-2026)
• 2.2 Neurodegenerative Disease Treatment Growth Trends by Regions
  • 2.2.1 Neurodegenerative Disease Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Neurodegenerative Disease Treatment Historic Market Share by Regions (2015-2020)
  • 2.2.3 Neurodegenerative Disease Treatment Forecasted Market Size by Regions (2021-2026)
• 2.3 Neurodegenerative Disease Treatment Industry Dynamic
  • 2.3.1 Neurodegenerative Disease Treatment Market Trends
  • 2.3.2 Neurodegenerative Disease Treatment Market Drivers
  • 2.3.3 Neurodegenerative Disease Treatment Market Challenges
  • 2.3.4 Neurodegenerative Disease Treatment Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Neurodegenerative Disease Treatment Players by Market Size
  • 3.1.1 Global Top Neurodegenerative Disease Treatment Players by Revenue (2015-2020)
  • 3.1.2 Global Neurodegenerative Disease Treatment Revenue Market Share by Players (2015-2020)
• 3.2 Global Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Neurodegenerative Disease Treatment Revenue
• 3.4 Global Neurodegenerative Disease Treatment Market Concentration Ratio
  • 3.4.1 Global Neurodegenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Treatment Revenue in 2019
• 3.5 Key Players Neurodegenerative Disease Treatment Area Served
• 3.6 Key Players Neurodegenerative Disease Treatment Product Solution and Service
• 3.7 Date of Enter into Neurodegenerative Disease Treatment Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disease Treatment Breakdown Data by Type

• 4.1 Global Neurodegenerative Disease Treatment Historic Market Size by Type (2015-2020)
• 4.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2021-2026)

5 Neurodegenerative Disease Treatment Breakdown Data by Application

• 5.1 Global Neurodegenerative Disease Treatment Historic Market Size by Application (2015-2020)
• 5.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Neurodegenerative Disease Treatment Market Size (2015-2026)
• 6.2 North America Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
• 6.3 North America Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
• 6.4 North America Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Neurodegenerative Disease Treatment Market Size (2015-2026)
• 7.2 Europe Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
• 7.3 Europe Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
• 7.4 Europe Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size (2015-2026)
• 8.2 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
• 8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
• 8.4 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia

9 Latin America

• 9.1 Latin America Neurodegenerative Disease Treatment Market Size (2015-2026)
• 9.2 Latin America Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
• 9.3 Latin America Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
• 9.4 Latin America Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size (2015-2026)
• 10.2 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
• 10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
• 10.4 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE

11Key Players Profiles

• 11.1 Allergan plc
  • 11.1.1 Allergan plc Company Details
  • 11.1.2 Allergan plc Business Overview
  • 11.1.3 Allergan plc Neurodegenerative Disease Treatment Introduction
  • 11.1.4 Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2015-2020))
  • 11.1.5 Allergan plc Recent Development
• 11.2 Bayer AG
  • 11.2.1 Bayer AG Company Details
  • 11.2.2 Bayer AG Business Overview
  • 11.2.3 Bayer AG Neurodegenerative Disease Treatment Introduction
  • 11.2.4 Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.2.5 Bayer AG Recent Development
• 11.3 F. Hoffmann La-Roche Ltd.
  • 11.3.1 F. Hoffmann La-Roche Ltd. Company Details
  • 11.3.2 F. Hoffmann La-Roche Ltd. Business Overview
  • 11.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Introduction
  • 11.3.4 F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.3.5 F. Hoffmann La-Roche Ltd. Recent Development
• 11.4 GlaxoSmithKline plc
  • 11.4.1 GlaxoSmithKline plc Company Details
  • 11.4.2 GlaxoSmithKline plc Business Overview
  • 11.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Introduction
  • 11.4.4 GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.4.5 GlaxoSmithKline plc Recent Development
• 11.5 Johnson & Johnson
  • 11.5.1 Johnson & Johnson Company Details
  • 11.5.2 Johnson & Johnson Business Overview
  • 11.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Introduction
  • 11.5.4 Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.5.5 Johnson & Johnson Recent Development
• 11.6 Merck KGaA
  • 11.6.1 Merck KGaA Company Details
  • 11.6.2 Merck KGaA Business Overview
  • 11.6.3 Merck KGaA Neurodegenerative Disease Treatment Introduction
  • 11.6.4 Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.6.5 Merck KGaA Recent Development
• 11.7 Novartis AG
  • 11.7.1 Novartis AG Company Details
  • 11.7.2 Novartis AG Business Overview
  • 11.7.3 Novartis AG Neurodegenerative Disease Treatment Introduction
  • 11.7.4 Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.7.5 Novartis AG Recent Development
• 11.8 Pfizer, Inc.
  • 11.8.1 Pfizer, Inc. Company Details
  • 11.8.2 Pfizer, Inc. Business Overview
  • 11.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Introduction
  • 11.8.4 Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.8.5 Pfizer, Inc. Recent Development
• 11.9 Sanofi
  • 11.9.1 Sanofi Company Details
  • 11.9.2 Sanofi Business Overview
  • 11.9.3 Sanofi Neurodegenerative Disease Treatment Introduction
  • 11.9.4 Sanofi Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.9.5 Sanofi Recent Development
• 11.10 Teva Pharmaceutical Industries Ltd.
  • 11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
  • 11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
  • 11.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Introduction
  • 11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
  • 11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development

12Analyst's Viewpoints/Conclusions

13Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer